Pleural effusion in patients with extrapleural primary malignancies
|
|
- Laurel Garrett
- 6 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Differentiation Between Malignant and Benign Pleural Effusion in Patients With Extra-Pleural Primary Malignancies Assessment With Positron Emission Tomography-Computed Tomography Jacob S. Toaff, MD,* Ur Metser, MD,* Maya Gottfried, MD, Odelia Gur, MD, Maher E. Deeb, MD, Gennady Lievshitz, MD,* Diego Mercer, MD, and Einat Even-Sapir, MD, PhD* Objectives: We sought to define an accurate diagnostic approach for differentiating benign from malignant pleural effusion on positron emission tomography computed tomography (PET-CT). Material and Methods: PET-CT studies of 31 patients with primary extrapleural malignancy and pleural effusion were reviewed retrospectively. CT parameters assessed were size and density (Hounsfield units, or HU) of the effusion and density (HU) and morphology of any solid pleural abnormality. Interpretation of PET data included review of the attenuation-corrected and nonattenuation-corrected images. Results: PET-CT parameters that were found to be significant in identifying malignant pleural effusion included focal increased uptake of 18-fluorodeoxyglucose in the pleura (P ) and the presence of solid pleural abnormalities on CT (P 0.002): the sensitivity was 86% and 71%, respectively, and the specificity was 90% for each of the 2 parameters. A PET-CT pattern composed of pleural uptake and increased effusion activity on nonattenuationcorrected images was associated with sensitivity of 95%, specificity of 80%, positive predictive value of 91%, negative predictive value of 89%, and accuracy of 90%. Conclusions: On PET-CT, the presence of concomitant pleural abnormalities is the most accurate criterion in determining the malignant nature of pleural effusion. Received October 13, 2004 and accepted for publication, after revision, December 12, From the *Departments of Nuclear Medicine, Hematology, and Radiology, Tel-Aviv Sourasky Medical Center; Lung Cancer Unit, Meir Hospital Sapir Medical Center, Tel-Aviv; Department of Cardio Thoracic Surgery, Shaare Zedek Medical Center, Jerusalem; and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Reprints: Einat Even-Sapir, MD, PhD, Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, 6 Weizman Street, Tel-Aviv, Israel. evensap@tasmc.health.gov.il. Copyright 2005 by Lippincott Williams & Wilkins ISSN: /05/ Key Words: PET-CT, pleural, effusion, malignant, lung cancer (Invest Radiol 2005;40: ) Pleural effusion in patients with extrapleural primary malignancies such as lung cancer, melanoma, or lymphoma may represent metastatic disease or reactive fluid collection or be the result of other nonmalignant disease processes such as infection. The diagnosis of malignant pleural effusion adversely affects the staging and prognosis and may alter the therapeutic approach. In nonsmall cell lung cancer, for instance, patients are unlikely to benefit from surgical resection if they have stage IIIB or stage IV disease. Malignant pleural effusion indicates locally extensive tumor (stage T4) and stage IIIB disease. 1 In Hodgkin disease and non-hodgkin lymphoma, malignant pleural effusion upgrades the stage to IV. 2 Several tests have been used to assess the nature of effusion in oncologic patients, including thoracocentesis with cytologic and/or biochemical analysis, computed tomography (CT), magnetic resonance imaging, blind or open-needle biopsy, and thoracoscopy. 3 Positron emission tomography (PET) using 18-fluorodeoxyglucose (FDG) has been shown to be an accurate imaging modality in differentiating benign from malignant disease processes, and previous reports have suggested that PET is an accurate diagnostic tool in differentiating benign from malignant pleural effusion in patients with malignant disease. 4 9 The CT part of the PET-CT may be the first to identify the presence of unexpected pleural effusion, increasing the need to differentiate malignant from benign pleural involvement when interpreting the PET-CT study. The purpose of the current study was to define the most accurate criteria to be used for such differentiation. We evaluated various CT and PET parameters, characterizing Investigative Radiology Volume 40, Number 4, April 2005
2 Investigative Radiology Volume 40, Number 4, April 2005 Differentiation Between Malignant and Benign Pleural Effusion pleural effusion in patients with primary extrapleural malignant diseases undergoing evaluation by PET-CT. MATERIALS AND METHODS Patient Population We conducted a retrospective study of 31 patients (25 men and 6 women; age range, years; mean age, 64 years) who had pleural effusion on PET-CT. Patients enrolled in the current study met the following inclusion criteria: (1) definitive pathologic diagnosis of a primary extrapleural malignancy and (2) definitive pathologic diagnosis of the pleural involvement. A positive malignant pleural effusion was concluded either by thoracocentesis of effusion or pleural biopsy performed within 6 weeks of the PET-CT examination. A negative pleural effusion was concluded if at least 2 cytologic results were negative for malignancy. Patients with pleural effusion who had (1) neither a cytologic nor a histologic assessment of the pleural disease, (2) a time gap longer than 6 weeks between thoracocentesis and PET-CT, or (3) a single negative cytologic result were not enrolled. PET-CT Scanning Patients were asked to fast for at least 4 hours before undergoing the examination. All patients had glucose levels less than 150 mg/dl. The patients received an intravenous injection of MBq (10 18 mci) of 18 F-FDG. Data were acquired minutes after injection using an integrated in-line PET-CT system (Discovery LS; GE Medical Systems). Data acquisition was as follows: CT scanning was performed first, from the head to the midthigh, with 140 kv, 80 ma, a tube rotation time of 0.5 seconds, a pitch of 6, and a 5-mm section thickness, which matched the PET section thickness. Immediately after CT scanning, a PET emission scan was obtained that covered the identical transverse field of view. The acquisition time was 5 minutes per table position. PET image datasets were reconstructed iteratively using CT data for attenuation correction, and coregistered images were displayed on a workstation (Xeleris, Elgems, Israel). Interpretation of 18 F-FDG PET-CT Images were interpreted by 2 specialists, in a consensus reading. Physicians interpreting the PET/CT data (U.M., E.E.S.) were blinded to the final diagnosis of the pleural abnormality. A third physician (Y.T.), who did not participate in the interpretation of the PET/CT, was responsible for assessment of the final diagnosis of the pleural findings. The parameters assessed on the CT data were size, location, and density (Hounsfield units, or HU) of the pleural effusion and density (HU) and morphology of any solid pleural abnormality. Pleural effusion size was defined as the maximal anteroposterior depth on supine images. Solid pleural abnormalities were defined as either diffuse or nodular thickening (Fig. 1). The interpretation of PET data included review of both the attenuation corrected (AC) and nonattenuation-corrected (NAC) images. On the AC images, 18 F-FDG uptake in the pleural effusion and pleural abnormalities was visually classified using a 3-grade-scale: grade 1 less than mediastinal activity; grade 2 equal or greater than mediastinal activity but less than liver activity; and grade 3 equal or grater than liver activity. On the NAC images, uptake in the fluid and/or pleural lesions was considered positive if equal to or greater than lung activity and negative if less (Fig. 2). The maximal standard uptake values (SUVs) of the fluid and pleural lesions were recorded. The PET CT-fused images were used to assess the exact anatomic location of 18 F-FDG uptake, thus allowing the differentiation between increased uptake in pleural layers and increased uptake within the effusion itself. Statistical Analysis The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy in differentiating benign from malignant pleural disease were calculated for CT and PET parameters. For nonparametric parameters (the presence of pleural abnormalities and FDG uptake relative to lung, mediastinal, and liver activity) 2 test and the Fisher exact test were used. For parametric parameters (HU, fluid size, and SUV) the Mann Whitney U test was used. A receiver operating curve analysis was used to assess the size, HU and SUV measured in pleural effusion, which best separated between benign and malignant effusion. Logistic regression for all CT and PET parameters was performed. Statistical analysis was performed using the SSPS for windows package, version 11 (Chicago, IL). RESULTS Malignant Effusion Twenty-one patients had malignant pleural disease based on thoracocentesis (n 19) and pleural biopsy (n 2). Primary sites of malignancy were lung cancer (nonsmall cell lung cancer, n 12; small cell lung cancer, n 2), lymphoma (n 5), ovarian cancer (n 1), and melanoma (n 1). On CT images, pleural effusion was unilateral in all patients but one. Pleura Eighteen of the 21 patients had pleural abnormalities. All solid pleural abnormalities detected on the CT part of the study in 15 patients were associated with increased uptake on AC and NAC images and were graded 3 on the AC images. The pleural surface was nodular (n 13), diffusely thickened (n 2), or normal (n 6) on CT. The mean density of these solid pleural abnormalities was HU, range HU. In 3 additional patients, focal increased uptake was detected in the corresponding location of the pleura, although CT imaging failed to detect a clear pleural abnormality. The 2005 Lippincott Williams & Wilkins 205
3 Toaff et al Investigative Radiology Volume 40, Number 4, April 2005 FIGURE 1. Malignant pleural involvement. The images from left to right represent CT, attenuation corrected PET, nonattenuationcorrected PET, and a fused PET-CT images. Upper row, a band of pleural thickening on CT image (arrow) with increased FDG uptake (arrow). Middle row, a pleural nodule on CT image (arrow) with corresponding increased FDG uptake (arrow). Bottom row, an area of increased pleural uptake on fused PET-CT images (arrow) is located in otherwise barely visible area of pleural thickening on CT image (arrow). Please note that despite the malignant pleural involvement, the effusion itself does not show increased FDG uptake both on the attenuation-corrected and nonattenuation-corrected PET images. mean SUV in pleural abnormalities was , range Effusion The mean effusion size was cm, range cm, and the mean density was HU, range-1-20 HU. On NAC PET images, 8 of 21 patients (38%) had increased uptake in the pleural effusion (equal or greater than lung uptake). On the AC PET images, uptake in the pleural effusion was graded 1 (less than mediastinal activity) in 9 patients, 2 (equal or greater than mediastinal activity but less than liver activity) in 4 patients, and 3 (equal or grater than liver activity) in 8 patients. The mean SUV in the pleural effusion was , range In 3 patients, we identified increased 18 F-FDG uptake within the fluid in dependent location (posterior when the patient is in supine position). Benign Effusion Ten patients had benign pleural effusion based on thoracocentesis (n 9) and thoracoscopy (n 1). Primary sites of malignancy were nonsmall cell lung cancer (n 5): small cell lung cancer (n 1) and lymphoma (n 4). The pleural surface was nodular in only 1 patient and normal in 206 the 9 remaining patients. On CT images, pleural effusion was unilateral in all cases. The mean size was cm, range cm, and the mean density was HU, range On NAC PET images, one patient had increased uptake in the pleural effusion. On the AC PET images, uptake in the pleural effusion was graded 1 in 4 patients, 2 in 4 patients, and 3 in 2 patients. Mean SUV in the pleural effusion was , range Differentiation Between Malignant and Benign Effusion Table 1 summarizes the results of received operating curve analysis for the size, density (HU), and uptake (SUV) in the pleural effusion and the sensitivity, specificity, PPV, NPV, and accuracy of CT and PET parameters in differentiating benign and malignant pleural disease. Two parameters were found statistically significant in differentiating between benign and malignant effusion on univariable analysis: solid pleural abnormalities on CT images detected in 15 of 21 patients with malignant pleural disease (P 0.002) and increased uptake in the pleural region on PET images detected in 18 of the 21 patients (P ). The sensitivity of PET in identifying pleural involvement was higher than that of CT alone. However, the 2005 Lippincott Williams & Wilkins
4 Investigative Radiology Volume 40, Number 4, April 2005 Differentiation Between Malignant and Benign Pleural Effusion FIGURE 2. Pleural effusion. The images from left to right represent CT, attenuation-corrected (AC) PET, nonattenuation-corrected (NAC) PET, and fused PET CT images. Upper row, the fluid (long arrow) is attenuated compared with the lung (short arrow) on NAC PET image. Midddle row, the fluid activity (long arrow) is similar to the activity in the aorta (arrowhead) on AC PET image. The PET lesion on the right is uptake in the primary lung tumor. This finding was clearly visualized when applying a lung CT windowing. The latter, however is not appropriate for assessment of pleural abnormalities on the CT data. Bottom row, fluid uptake (long arrow) is similar to that in liver (arrowhead) on AC PET image and to the lung (arrowhead) on NAC PET image. CT allowed us, on the fused images, to accurately locate the increased FDG uptake in the pleura and not in the adjacent fluid, lung, or chest wall. Only 1 of the 10 patients with benign effusion had nodular pleural thickening with increased FDG uptake (false positive). This patient had nonsmall cell cancer of the lung, and his effusion was parapneumonic. Although increased uptake within the fluid on NAC was associated with a high PPV (89%), none of the parameters of the effusion itself was statistically significant on univariable analysis in differentiating benign from malignant effusion. For assessment of the pleural fluid alone, we used a logistic regression analysis to find a combination of parameters that may assist in differentiating between benign and malignant effusion. Using a stepwise forward selection method, a model was obtained that identified the combination of pleural effusion size (P 0.016) and increased uptake on NAC PET images in the effusion (P 0.013) as adequate for differentiation. The probability for malignancy based on combination of these 2 parameters is illustrated in Table 2. Increased fluid FDG uptake on NAC images had a probability for malignancy, which varied between 81% and 98% as fluid size increased. Two of 3 patients with malignant effusion who did not have a concomitant pleural abnormality had increased FDG uptake on NAC PET. A PET-CT pattern composed of pleural uptake and increased effusion activity on NAC images was associated with sensitivity of 95%, specificity of 80%, PPV of 91%, NPV of 89%, and accuracy of 90%. DISCUSSION Metastatic involvement of the pleura may be present in various extrapleural malignancies. However, not all cases of pleural effusion found in these patients indicate metastatic disease and may often be the result of cardiac failure, infection, or other benign causes. Malignant pleural effusion upgrades the stage, precludes resection of the primary tumor, and heralds a grave prognosis for the patient; hence, it is of major importance to correctly differentiate between benign and malignant pleural effusion. 1,2 Morphologic imaging, including CT and magnetic resonance imaging, cannot be relied 2005 Lippincott Williams & Wilkins 207
5 Toaff et al Investigative Radiology Volume 40, Number 4, April 2005 TABLE 1. The Diagnostic Accuracy of CT and PET in Differentiating Malignant From Benign Pleural Effusion Parameter SEN SPE PPV NPV AC CT Presence of solid pleural abnormalities Effusion density HU cutoff* Effusion size 10-cm cutoff* cm cutoff* PET Effusion Increased uptake on AC images Grade 3 cutoff Grade 2 cutoff SUV 1.7 cutoff* Increased uptake on NAC images Pleural abnormalities Increased uptake on PET images *Determined by ROC analysis. CT, computed tomography; PET, positron emission tomography; SEN, sensitivity; SPEC, specificity; PPV, positive predictive value; NPV, negative predictive value; AC, accuracy. TABLE 2. Logistic Regression Analysis: The Probability of Malignant Effusion Based on a Combination of Pleural Effusion Size and Increased Uptake in the Effusion on Nonattenuation-Corrected Images Increased FDG Uptake in Pleural Effusion (NAC) Pleural Effusion Size (cm) Probability of Malignant Effusion (%) No 1 12 Yes 1 81 No 3 21 Yes 3 88 No 6 38 Yes 6 95 No 9 60 Yes 9 98 upon when performed alone Invasive modalities often are warranted to establish the diagnosis of the effusion, the most common being thoracocentesis. Cytologic analysis of pleural effusion identifies malignancy in approximately two thirds of the cases of malignant pleural effusion. 13 Often, a repeated thoracocentesis is performed, which identifies a positive specimen in another 30% of cases. 14 Similarly, biochemical analysis of the pleural fluid fails to accurately differentiate between benign and malignant effusion Thoracoscopy has an excellent diagnostic yield ( 95%) 18 but is invasive and requires a trained surgical staff and appropriate facilities. 208 Several recent studies have shown FDG-PET to have an important role in differentiating benign from malignant pleural effusion in patients with nonpleural malignancies with sensitivity ranging between 88% and 100% and specificity of 67% to 94%. 4 9 Schaffler et al, 8 in a study involving 92 patients with nonsmall cell lung cancer and pleural abnormalities, showed that the respective sensitivity, specificity, PPV, NPV, and accuracy of FDG-PET in detection of pleural involvement were 100%, 71%, 63%, 100%, and 80%. When CT findings performed separately were combined with those of PET, the specificity increased from 71% to 76%, the PPV increased from 63% to 67%, and the accuracy increased from 80% to 84%. The relatively low specificity and PPV were caused by false positive increased FDG uptake in infection. Duysinx et al 7 evaluated the ability of FDG-PET to differentiate between benign and malignant pleural disease in 98 patients who presented with pleural thickening and/or an exudative pleural effusion. The respective sensitivity, specificity, PPV, and NPV were 96.8%, 88.5%, 93.8%, and 93.9%. Functional imaging with FDG has been reported to be of clinical value in various human malignancies. 19,20 Recently, the use of PET-CT hybrid systems for the evaluation of patients with malignant diseases has become more common. Detection of a pleural effusion on the CT part of the study may be, in some cases, the first imaging modality to identify the presence of pleural effusion. When interpreting the PET-CT study, a question emerges as to what is the most accurate diagnostic approach to determine the nature of this effusion. The anatomic congruity between the CT and PET scans performed consecutively without moving the patient 2005 Lippincott Williams & Wilkins
6 Investigative Radiology Volume 40, Number 4, April 2005 Differentiation Between Malignant and Benign Pleural Effusion between scans provides an option to define the precise anatomic location of increased FDG uptake (ie, in areas of nodular pleural thickening, in pleural fluid, or normal appearing pleural surface). The aim of this study was to define an approach to pleural effusion based on various parameters that may be determined on the CT and PET parts of the study. As indicated by the results of the current study, abnormality of the pleura itself is the most accurate sign for malignancy when assessing the nature of pleural effusion detected on PET-CT. PET was more sensitive than CT alone in identifying pleural involvement. In addition to being positive in 15 patients with a corresponding pleural abnormality on CT, it identified pleural involvement in 3 additional patients in whom increased uptake was detected in the pleural layer, although no corresponding CT abnormality was identified. This pleural involvement would have been overlooked on CT alone. However, CT allowed us, based on the fused images, to accurately relate this increased FDG uptake to the pleura and not to adjacent fluid, lung, or chest wall. A single case of false-positive increased pleural uptake with morphologic CT pleural abnormalities was caused by infection. As for the effusion itself, the combination of large effusion with increased FDG uptake on NAC images was found to be highly suggestive for malignancy, reaching a probability of 98%. Identifying this effusion pattern was of particular importance in patients who did not have concomitant pleural abnormalities. In this study, better results were achieved for NAC images than for AC images in differentiating malignant from benign effusion. In a previous publication by Wahl et al, 21 it was shown that in lung cancer, the target-to-background (ie, lesion to blood) ratios are significantly higher for NAC images than for AC images. The latter could also be the cause for the current study s results assessing chest abnormalities. Focal increased uptake within the posterior portion of the fluid, is a finding that, although relatively infrequent (3/21 patients with malignant pleural effusion), was highly specific for malignancy. A possible explanation for this finding may be uptake in malignant cells accumulating in dependent location when data are acquired in the supine position. The main limitation of our study is the relatively small number of patients, a result of our strict inclusion criteria. Studies with a larger number of patients need to be conducted to validate our results. In addition, this study was retrospective. However, the physicians interpreting the PET CT were blinded to the final diagnosis of the pleural abnormality whereas a third physician who did not participate in imaging interpretation was responsible for assessment of the final diagnosis. In conclusion, the most accurate parameter to be considered when identifying pleural effusion on PET-CT is the presence of increased FDG uptake in the pleura, whether associated with pleural CT abnormality or not. Increased FDG uptake in the effusion itself on NAC images, especially in large effusions, has a high probability for malignant effusion. ACKNOWLEDGMENTS The authors thank Rony Rona for her assistance with the cytologic analysis of the pleural effusion. REFERENCES 1. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111: Armitage JD, Longo DL. Malignancies of lymphoid cells. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison s Principles of Internal Medicine. 15th ed. New York: McGraw-Hill; 2001: Roberts JR, Blum MG, Arildsen R, et al. Prospective comparison of radiology, thoracoscopic, and pathologic staging in patients with early non-small cell lung cancer. Ann Thorac Surg. 1999;68: Buchmann I, Guhlmann CA, Elsner K, et al. F-18-FDG-PET for primary diagnosis differential diagnosis of pleural processes. Nuklearmedizin. 1999;38: Gupta NC, Rogers JS, Graeber GM, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest. 2002;122: Erasmus JJ, McAdams HP, Rossi SE, et al. FDG PET of pleural effusions in patients with non-small cell lung cancer. Am J Roentgenol. 2000;175: Duysinx B, Nguyen D, Louis R, et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest. 2004;125: Schaffler GJ, Wolf G, Schoellnast H, et al. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET. Radiology. 2004;231: Kramer H, Pieterman RM, Slebos DJ, et al. PET for the evaluation of pleural thickening observed on CT. J Nucl Med. 2004;45: Falaschi F, Battolla L, Mascalchi M, et al. Usefulness of MR signal intensity in distinguishing benign from malignant pleural disease. AJR Am J Roentgenol. 1996;166: Shiono T, Yoshikawa K, Takenaka E, Hisamatsu K. MR imaging of pleural and peritoneal effusion. Radiat Med. 1993;11: Arenas-Jimenez J, Alonso-Charterina S, Sanchez-Paya J, et al. Evaluation of CT findings for diagnosis of pleural effusions. Eur Radiol. 2000;10: Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med. 1997;156: Light RW, Eozan YS, Ball WC. Cells in pleural fluid: their value in differential diagnosis. Arch Intern Med. 1973;132: Burgess LJ, Maritz FJ, Taljaard FFJ. Comparative analysis of the biochemical parameters used to distinguish between pleural transudates and exudates. Chest. 1995;107: Ceyhan BB, Demiralp E, Celikel T. Analysis of pleural effusions using flow cytometry. Respiration. 1996;63: Metintas M, Ozdemir N, Solak M, et al. Chromosome analysis in pleural effusions: efficiency of this method in the differential diagnosis of pleural effusions. Respiration. 1994;61: Menzies R, Charbonneau M. Thoracoscopy for the diagnosis of pleural disease. Ann Intern Med. 1991;114: Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231: Miller E, Lerman H, Gutman M, et al. The clinical impact of camerabased positron emission tomography imaging in patients with recurrent colorectal cancer. Invest Radiol. 2004;39: Wahl RL, Neuhoff A, Kison P, et al. Qualitative criteria for determining if a solitary pulmonary nodule is malignant or benign on FDG PET: impact of not accounting correctly for soft tissue attenuation. J Nucl Med. 1999;39(suppl): Lippincott Williams & Wilkins 209
PET-CT findings in surgically transposed ovaries
The British Journal of Radiology, 79 (2006), 110 115 1,2,3 R ZISSIN, MD, 1 U METSER, MD, 1 H LERMAN, MD, 1 G LIEVSHITZ, MD, 4 T SAFRA, MD and 1,3 E EVEN-SAPIR, MD, PhD Department of 1 Nuclear Medicine
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More informationPositron Emission Tomography in Lung Cancer
May 19, 2003 Positron Emission Tomography in Lung Cancer Andrew Wang, HMS III Patient DD 53 y/o gentleman presented with worsening dyspnea on exertion for the past two months 30 pack-year smoking Hx and
More informationLos Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010
Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationMalignant Effusions. Anantham Devanand Respiratory and Critical Care Medicine Singapore General Hospital
Malignant Effusions Anantham Devanand Respiratory and Critical Care Medicine Singapore General Hospital Malignant Effusions Definition: Presence of malignant cells in the pleural space 75% are caused by
More information1 Introduction. 2 Materials and methods. LI Na 1 LI Yaming 1,* YANG Chunming 2 LI Xuena 1 YIN Yafu 1 ZHOU Jiumao 1
Nuclear Science and Techniques 20 (2009) 354 358 18 F-FDG PET/CT in diagnosis of skeletal metastases LI Na 1 LI Yaming 1,* YANG Chunming 2 LI Xuena 1 YIN Yafu 1 ZHOU Jiumao 1 1 Department of Nuclear Medicine,
More informationImaging of pleural masses: Which to choose? Republished article $
Respiratory Medicine CME (2008) 1, 10 14 respiratory MEDICINE CME CME ARTICLE Imaging of pleural masses: Which to choose? Republished article $ Aaron S. Bruns, John G. Mastronarde Division of Pulmonary
More informationFDG-PET Findings in an Ovarian Endometrioma: A Case Report
FDG-PET Findings in an Ovarian Endometrioma: A Case Report Jia-Huei Lin 1, Victor Chit-kheng Kok 2, Jian-Chiou Su 3 1 Department of Nuclear medicine, Kuang Tien General Hospital, Sha-Lu, Taichung, Taiwan
More informationUtility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer
Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationPOSITRON EMISSION TOMOGRAPHY (PET)
Status Active Medical and Behavioral Health Policy Section: Radiology Policy Number: V-27 Effective Date: 08/27/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationPET/CT Frequently Asked Questions
PET/CT Frequently Asked Questions General Q: Is FDG PET specific for cancer? A: No, it is a marker of metabolism. In general, any disease that causes increased metabolism can result in increased FDG uptake
More informationRadiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh
Radiological staging of lung cancer Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh Bronchogenic Carcinoma Accounts for 14% of new cancer diagnoses in 2012. Estimated to kill ~150,000
More informationTesticular relapse of non-hodgkin Lymphoma noted on FDG-PET
Testicular relapse of non-hodgkin Lymphoma noted on FDG-PET Stephen D. Scotti 1*, Jennifer Laudadio 2 1. Department of Radiology, North Carolina Baptist Hospital, Winston-Salem, NC, USA 2. Department of
More informationEarly detection of prostate cancer (PCa) may feasibly lead
ORIGINAL ARTICLE C-11 Choline PET/CT Imaging for Differentiating Malignant From Benign Prostate Lesions Xin Li, MD,* Qi Liu, MD, PhD,* Muwen Wang, MD, PhD,* Xunbo Jin, MD,* Qingwei Liu, MD, PhD,* Shuzhan
More informationEndobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
More informationUpdate in Lymphoma Imaging
Update in Lymphoma Imaging Victorine V. Muse, MD Lymphoma Update in Lymphoma Imaging Victorine V Muse, MD Heterogeneous group of lymphoid neoplasms divided into two broad histological categories Hodgkin
More informationNoninvasive Differential Diagnosis of Pulmonary Nodules Using the Standardized Uptake Value Index
doi: 10.5761/atcs.oa.14-00241 Original Article Noninvasive Differential Diagnosis of Pulmonary Nodules Using the Standardized Uptake Value Index Satoshi Shiono, MD, 1 Naoki Yanagawa, MD, 2 Masami Abiko,
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationAlthough not as common as focal hepatic masses, solid
Solid Splenic Masses: Evaluation with F-FDG PET/CT Ur Metser, MD 1,2 ; Elka Miller, MD 2 ; Ada Kessler, MD 2 ; Hedva Lerman, MD 1 ; Gennady Lievshitz, MD 1 ; Ran Oren, MD 3 ; and Einat Even-Sapir, MD,
More informationPositron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin s Lymphomas (NHL)
CANCER BIOTHERAPY & RADIOPHARMACEUTICALS Volume 16, Number 4, 2001 Mary Ann Liebert, Inc. Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin s Lymphomas (NHL) F. Najjar, R. Hustinx, G.
More informationImaging Decisions Start Here SM
Owing to its high resolution and wide anatomic coverage, dynamic first-pass perfusion 320-detector-row CT outperforms PET/CT for distinguishing benign from malignant lung nodules, researchers from Japan
More informationEfficacy of Computed Tomography (CT) Attenuation Values and CT Findings in the Differentiation of Pleural Effusion
Signature: Pol J Radiol, 2017; 82: 100-105 DOI: 10.12659/PJR.898963 ORIGINAL ARTICLE Received: 2016.04.10 Accepted: 2016.05.31 Published: 2017.02.19 Authors Contribution: A Study Design B Data Collection
More informationBone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When PET Scans Findings Are Equivocal: A Case Report
Bone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When Scans Findings Are Equivocal: A Case Report Yuk-Wah Tsang 1, Jyh-Gang Leu 2, Yen-Kung Chen 3, Kwan-Hwa Chi 1,4
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationDeppen S, et al. Annals of Thoracic Surgery 2011;92:
Deppen S, et al. Annals of Thoracic Surgery 2011;92:428-33. http://www.nationmaster.com/graph/ mor_his-mortality-histoplasmosis http://www.humirarems.com/brochure.aspx Baddley, John W., et al. Emerging
More informationMEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES
MEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES Although response is not the primary endpoint of this trial, subjects with measurable disease will be assessed by standard criteria. For the purposes of this
More informationFDG-PET/CT for cancer management
195 REVIEW FDG-PET/CT for cancer management Hideki Otsuka, Naomi Morita, Kyo Yamashita, and Hiromu Nishitani Department of Radiology, Institute of Health Biosciences, The University of Tokushima, Graduate
More informationWHAT DOES PET IMAGING ADD TO CONVENTIONAL STAGING OF HEAD AND NECK CANCER PATIENTS?
doi:10.1016/j.ijrobp.2006.12.044 Int. J. Radiation Oncology Biol. Phys., Vol. 68, No. 2, pp. 383 387, 2007 Copyright 2007 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/07/$ see front
More informationUtility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC)
Utility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC) Poster No.: C-1360 Congress: ECR 2015 Type: Scientific Exhibit Authors:
More informationValue of true whole-body FDG- PET/CT scanning protocol in oncology and optimization of its use based on primary malignancy
Value of true whole-body FDG- PET/CT scanning protocol in oncology and optimization of its use based on primary malignancy Ronnie Sebro MD, Ph.D Carina Mari Aparici MD, Miguel Hernandez Pampaloni MD, PhD
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationResearch Article Prevalence of Clinically Significant Extraosseous Findings on Unenhanced CT Portions of 18 F-Fluoride PET/CT Bone Scans
The Scientific World Journal Volume 2012, Article ID 979867, 5 pages doi:10.1100/2012/979867 The cientificworldjournal Research Article Prevalence of Clinically Significant Extraosseous Findings on Unenhanced
More informationBreast Cancer PET/CT Imaging Protocol
Breast Cancer PET/CT Imaging Protocol Scanning Protocol: Patients are scanned from the top of the neck through the pelvis. Arms-up position is used to avoid beam-hardening artifact in the chest and abdomen.
More informationRyan Niederkohr, M.D. Slides are not to be reproduced without permission of author
Ryan Niederkohr, M.D. CMS: PET/CT CPT CODES 78814 Limited Area (e.g., head/neck only; chest only) 78815 78816 Regional (skull base to mid-thighs) True Whole Body (skull vertex to feet) SELECTING FIELD
More informationDoes PET/CT Have an Additional Value in Detection of Osteolytic Bone Metastases.
Egyptian J. Nucl. Med., Vol 2, No. 2, Dec. 2009 65 ONCOLOGY, Original Article Does PET/CT Have an Additional Value in Detection of Osteolytic Bone Metastases. R. Riad, M.D.*, M. Awad, M.D. **, E. Eldebawy,
More informationPET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET
Positron Emission Tomography (PET) When calling Anthem (1-800-533-1120) or using the Point of Care authorization system for a Health Service Review, the following clinical information may be needed to
More informationDiffuse high-attenuation within mediastinal lymph nodes on non-enhanced CT scan: Usefulness in the prediction of benignancy
Diffuse high-attenuation within mediastinal lymph nodes on non-enhanced CT scan: Usefulness in the prediction of benignancy Poster No.: C-1785 Congress: ECR 2012 Type: Authors: Keywords: DOI: Scientific
More informationBilateral hilar 18 F-FDG avid foci are often noted on
Bilateral Hilar Foci on F-FDG PET Scan in Patients Without Lung Cancer: Variables Associated with Benign and Malignant Etiology Maroun Karam 1, Shayna Roberts-Klein 1, Narendra Shet 2, Johanna Chang 2,
More informationFDG-PET value in deep endometriosis
Gynecol Surg (2011) 8:305 309 DOI 10.1007/s10397-010-0652-6 ORIGINAL ARTICLE FDG-PET value in deep endometriosis A. Setubal & S. Maia & C. Lowenthal & Z. Sidiropoulou Received: 3 December 2010 / Accepted:
More informationMolecular Imaging and Cancer
Molecular Imaging and Cancer Cancer causes one in every four deaths in the United States, second only to heart disease. According to the U.S. Department of Health and Human Services, more than 512,000
More informationWhat to Do with Small Lung Nodules Hanh Vu Nghiem, MD William Beaumont Hospital Royal Oak, Michigan
What to Do with Small Lung Nodules Hanh Vu Nghiem, MD William Beaumont Hospital Royal Oak, Michigan Small Lung Nodules What to do with small lung nodules? We biopsy them when requested What are our accuracy
More informationPET/CT for Therapy Assessment in Oncology
PET/CT for Therapy Assessment in Oncology Rodolfo Núñez Miller, M.D. Nuclear Medicine Section Division of Human Health International Atomic Energy Agency Vienna, Austria Clinical Applications of PET/CT
More informationThe solitary pulmonary nodule: Assessing the success of predicting malignancy
The solitary pulmonary nodule: Assessing the success of predicting malignancy Poster No.: C-0829 Congress: ECR 2010 Type: Scientific Exhibit Topic: Chest Authors: R. W. K. Lindsay, J. Foster, K. McManus;
More informationRecent advances in positron emission tomography (PET)
Evaluation of Semiquantitative Assessments of Fluorodeoxyglucose Uptake on Positron Emission Tomography Scans for the Diagnosis of Pulmonary Malignancies 1 to 3 cm in Size Yasuomi Ohba, MD, Hiroaki Nomori,
More informationIntroduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT
Introduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT protocols Tips Leukaemia / lymphoma: ~ 35% acute lymphoblastic
More informationU"lity of Screening and Surveillance Using Nuclear Medicine Methodology. (Lung Cancer) Michael M. Graham, PhD, MD University of Iowa
U"lity of Screening and Surveillance Using Nuclear Medicine Methodology (Lung Cancer) Michael M. Graham, PhD, MD University of Iowa American Cancer Society IniBal Guideline Clinicians with access to high-
More informationobjectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University
objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University To determine the regions of physiologic activity To understand
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationThe Imaging Journey of Patients with Malignant Pleural Mesothelioma: Experience of a Tertiary Mesothelioma MDT
The Imaging Journey of Patients with Malignant Pleural Mesothelioma: Experience of a Tertiary Mesothelioma MDT V. Lam, J. Brozik, A. J. Sharkey, A. Bajaj, D. T. Barnes Glenfield Hospital, Leicester, United
More informationMay-Lin Wilgus. A. Study Purpose and Rationale
Utility of a Computer-Aided Diagnosis Program in the Evaluation of Solitary Pulmonary Nodules Detected on Computed Tomography Scans: A Prospective Observational Study May-Lin Wilgus A. Study Purpose and
More informationValidation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules
1 Stanford School of Medicine, Stanford, California, USA; 2 Duke University, Durham, North Carolina, USA; 3 Medical University of South Carolina, Charleston, South Carolina, USA; 4 VA Palo Alto Health
More informationThoracostomy: An Update on Imaging Features and Current Surgical Practice
Thoracostomy: An Update on Imaging Features and Current Surgical Practice Robert D. Ambrosini, MD, PhD, Christopher Gange, MD, Katherine Kaproth-Joslin, MD, PhD, Susan Hobbs, MD, PhD Department of Imaging
More informationPositron emission tomography predicts survival in malignant pleural mesothelioma
Flores et al General Thoracic Surgery Positron emission tomography predicts survival in malignant pleural mesothelioma Raja M. Flores, MD, a Timothy Akhurst, MD, b Mithat Gonen, PhD, c Maureen Zakowski,
More informationSmall Pulmonary Nodules: Our Preliminary Experience in Volumetric Analysis of Doubling Times
Small Pulmonary Nodules: Our Preliminary Experience in Volumetric Analysis of Doubling Times Andrea Borghesi, MD Davide Farina, MD Roberto Maroldi, MD Department of Radiology University of Brescia Brescia,
More informationCopyright 2007 IEEE. Reprinted from 4th IEEE International Symposium on Biomedical Imaging: From Nano to Macro, April 2007.
Copyright 27 IEEE. Reprinted from 4th IEEE International Symposium on Biomedical Imaging: From Nano to Macro, April 27. This material is posted here with permission of the IEEE. Such permission of the
More informationImaging of Pulmonary Tuberculosis with 18 F-Fluoro-Deoxy-Glucose and
Send Orders for Reprints to reprints@benthamscience.net The Open Nuclear Medicine Journal, 2014, 6, 17-21 17 Open Access Imaging of Pulmonary Tuberculosis with 18 F-Fluoro-Deoxy-Glucose and 18 F-Ethylcholine
More informationRole of CT imaging to evaluate solitary pulmonary nodule with extrapulmonary neoplasms
Original Research Article Role of CT imaging to evaluate solitary pulmonary nodule with extrapulmonary neoplasms Anand Vachhani 1, Shashvat Modia 1*, Varun Garasia 1, Deepak Bhimani 1, C. Raychaudhuri
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationREVIEW. Distinguishing benign from malignant adrenal masses
Cancer Imaging (2003) 3, 102 110 DOI: 10.1102/1470-7330.2003.0006 CI REVIEW Distinguishing benign from malignant adrenal masses Isaac R Francis Professor of Radiology, Department of Radiology, University
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationStaging recurrent ovarian cancer with 18 FDG PET/CT
ONCOLOGY LETTERS 5: 593-597, 2013 Staging recurrent ovarian cancer with FDG PET/CT SANJA DRAGOSAVAC 1, SOPHIE DERCHAIN 2, NELSON M.G. CASERTA 3 and GUSTAVO DE SOUZA 2 1 DIMEN Medicina Nuclear and PET/CT
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationMulticentre analysis of incidental findings on low resolution CT attenuation correction images : an extended study
Multicentre analysis of incidental findings on low resolution CT attenuation correction images : an extended study Coward, J, Lawson, R, Kane, T, Elias, M, Howes, A, Birchall, J and Hogg, P http://dx.doi.org/10.1259/bjr.20150555
More informationResearch Article Revisiting the Marrow Metabolic Changes after Chemotherapy in Lymphoma: A Step towards Personalized Care
International Molecular Imaging Volume 2011, Article ID 942063, 6 pages doi:10.1155/2011/942063 Research Article Revisiting the Marrow Metabolic Changes after Chemotherapy in Lymphoma: A Step towards Personalized
More informationLarry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017
Larry Tan, MD Thoracic Surgery, HSC Community Cancer Care Educational Conference October 27, 2017 To describe patient referral & triage for the patient with suspected lung cancer To describe the initial
More informationFrozen Section Library: Pleura
Frozen Section Library: Pleura For other titles published in this series, go to www.springer.com/series/7869 Frozen Section Library: Pleura Philip T. Cagle, MD Weill Medical College of Cornell University,
More informationDiagnostic value of fluorine-18 fluorodeoxyglucose positron emission tomography / computed tomography in fever of unknown origin
175 18 F-FDG PET /CT 1* 2* 1 1 1 1 1 1 1. 100034 2. 100850 18 F-FDG PET /CT fever of unknown origin FUO 2010 8 2013 4 51 FUO FDG PET /CT 3 FDG PET /CT t 51 FUO 32 9 7 3 FDG PET FUO 27 52. 9% 14 27. 5%
More informationWell-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report
Showa Univ J Med Sci 25 1, 67 72, March 2013 Case Report Well-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report Yuri TOMITA
More informationWith recent advances in diagnostic imaging technologies,
ORIGINAL ARTICLE Management of Ground-Glass Opacity Lesions Detected in Patients with Otherwise Operable Non-small Cell Lung Cancer Hong Kwan Kim, MD,* Yong Soo Choi, MD,* Kwhanmien Kim, MD,* Young Mog
More informationPersistent Spontaneous Pneumothorax for Four Years: A Case Report
303) Persistent Spontaneous Pneumothorax for Four Years: A Case Report Mizuno Y., Iwata H., Shirahashi K., Matsui M., Takemura H. Department of General and Cardiothoracic Surgery, Graduate School of Medicine,
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationThe Diagnostic Value of PET/CT in Breast Cancer Recurrence and Metastases
Original Paper, Oncology. The Diagnostic Value of PET/CT in Breast Cancer Recurrence and Metastases Taalab, Kh. 1 ; Abutaleb, AS 1 ; Moftah, SG 2 ; Abdel-Mutaleb, MG 2 and Abdl-Mawla, YA 2. 1 Military
More informationEvaluation of Lung Cancer Response: Current Practice and Advances
Evaluation of Lung Cancer Response: Current Practice and Advances Jeremy J. Erasmus I have no financial relationships, arrangements or affiliations and this presentation will not include discussion of
More informationEfficacy of ultrasonography and computed tomography in differentiating transudate from exudate in patients with pleural effusion
Efficacy of ultrasonography and computed tomography in differentiating transudate from exudate in patients with pleural effusion Purpose: To evaluate USG and CT imaging findings in differentiating transudative
More informationAcknowledgments. A Specific Diagnostic Task: Lung Nodule Detection. A Specific Diagnostic Task: Chest CT Protocols. Chest CT Protocols
Personalization of Pediatric Imaging in Terms of Needed Indication-Based Quality Per Dose Acknowledgments Duke University Medical Center Ehsan Samei, PhD Donald Frush, MD Xiang Li PhD DABR Cleveland Clinic
More informationDual-time-point FDG-PET/CT Imaging of Temporal Bone Chondroblastoma: A Report of Two Cases
Dual-time-point FDG-PET/CT Imaging of Temporal Bone Chondroblastoma: A Report of Two Cases Akira Toriihara 1 *, Atsunobu Tsunoda 2, Akira Takemoto 3, Kazunori Kubota 1, Youichi Machida 1, Ukihide Tateishi
More informationUltrasound-guided pleural cutting needle biopsy: accuracy and factors influencing diagnostic yield
Original Article Ultrasound-guided pleural cutting needle biopsy: accuracy and factors influencing diagnostic yield Yuxin Zhang 1#, Jiaxin Tang 2#, Xinghua Zhou 1, Dazhi Zhou 1, Jinlin Wang 2, Qing Tang
More informationPET with the glucose analog, 18 F-FDG PET, is increasingly
18 F-FDG PET/CT in Evaluating Non-CNS Pediatric Malignancies Mitsuaki Tatsumi 1, John H. Miller 2, and Richard L. Wahl 1 1 Division of Nuclear Medicine, Department of Radiology, The Johns Hopkins Medical
More informationF-2-fluoro-2-deoxyglucose uptake in or adjacent to blood vessel walls
15 REVIEW 18 F-2-fluoro-2-deoxyglucose uptake in or adjacent to blood vessel walls Yoichi Otomi 1, Hideki Otsuka 2, Kaori Terazawa 1, Hayato Nose 1,3, Michiko Kubo 1, Kazuhide Yoneda 1, Kaoru Kitsukawa
More informationAustin Radiological Association Nuclear Medicine Procedure PET SODIUM FLUORIDE BONE SCAN (F-18 NaF)
Austin Radiological Association Nuclear Medicine Procedure PET SODIUM FLUORIDE BONE SCAN (F-18 NaF) Overview Indication Sodium Fluoride F18 injection is a radioactive diagnostic agent for positron emission
More informationRadiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer
Radiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer Poster No.: C-0654 Congress: ECR 2011 Type: Scientific Paper Authors:
More informationNew Visions in PET: Surgical Decision Making and PET/CT
New Visions in PET: Surgical Decision Making and PET/CT Stanley J. Goldsmith, MD Director, Nuclear Medicine Professor, Radiology & Medicine New York Presbyterian Hospital- Weill Cornell Medical Center
More informationDirect Comparison of 18 F-FDG PET and PET/CT in Patients with Colorectal Carcinoma
Direct Comparison of F-FDG PET and PET/CT in Patients with Colorectal Carcinoma Christian Cohade, MD; Medhat Osman, MD, PhD; Jeffrey Leal, BA; and Richard L. Wahl, MD Division of Nuclear Medicine, Russell
More informationCan aortic aneurysm growth rate be predicted in clinical practice using 18-fluorodeoxyglucose positron emission tomography (18-FDG PET)?
Can aortic aneurysm growth rate be predicted in clinical practice using 18-fluorodeoxyglucose positron emission tomography (18-FDG PET)? Poster No.: C-1743 Congress: ECR 2011 Type: Authors: Keywords: DOI:
More informationCase Reports: Tumor Detection by Diffusion-Weighted MRI and ADC-Mapping with Correlation to PET/CT Results
Case Reports: Tumor Detection by Diffusion-Weighted MRI and ADC-Mapping with Correlation to PET/CT Results Matthias Philipp Lichy, M.D.; Philip Aschoff, M.D.; Christina Pfannenberg, M.D.; Schlemmer Heinz-Peter,
More informationUsing PET/CT in Prostate Cancer
Using PET/CT in Prostate Cancer Legal Disclaimer These materials were prepared in good faith by MITA as a service to the profession and are believed to be reliable based on current scientific literature.
More informationCharacterization of the Solitary Pulmonary Nodule: 18 F-FDG PET Versus Nodule-Enhancement CT
PET vs CT of Solitary Pulmonary Nodules Nuclear Medicine Original Research C D E M N E U T R Y L I M C I G O F I N G Characterization of the Solitary Pulmonary Nodule: 18 F-FDG PET Versus Nodule-Enhancement
More informationFDG PET/CT in Lung Cancer Read with the experts. Homer A. Macapinlac, M.D.
FDG PET/CT in Lung Cancer Read with the experts Homer A. Macapinlac, M.D. Patient with suspected lung cancer presents with left sided chest pain T3 What is the T stage of this patient? A) T2a B) T2b C)
More informationNegative axillary sentinel node (SN) biopsy (SNB) Improved Sentinel Node Identification by SPECT/CT in Overweight Patients with Breast Cancer
Improved Sentinel Node Identification by SPECT/CT in Overweight Patients with Breast Cancer Hedva Lerman 1, Gennady Lievshitz 1, Osnat Zak 2, Ur Metser 1,3, Shlomo Schneebaum 3,4, and Einat Even-Sapir
More informationDiagnostic performance of unenhanced computed tomography and 18 F- fluorodeoxyglucose positron emission tomography in indeterminate adrenal tumours
Received: 8 June 2017 Revised: 3 August 2017 Accepted: 11 August 2017 DOI: 10.1111/cen.13448 ORIGINAL ARTICLE Diagnostic performance of unenhanced computed tomography and 18 F- fluorodeoxyglucose positron
More informationUsefulness of Delayed Scan of FDG PET for the Diagnosis of Lymph Node Metastasis in Non-Small Cell Lung Cancer
Yamanashi Med. J. 31(1), 1 8, 20161 Original article Usefulness of Delayed Scan of FDG PET for the Diagnosis of Lymph Node Metastasis in Non-Small Cell Lung Cancer Satoshi KATO 1), Atsushi NAMBU 2) and
More informationCLINICAL PRESENTATION AND RADIOLOGY QUIZ QUESTION
Donald L. Renfrew, MD Radiology Associates of the Fox Valley, 333 N. Commercial Street, Suite 100, Neenah, WI 54956 4/30/2011 Radiology Quiz of the Week # 18 Page 1 CLINICAL PRESENTATION AND RADIOLOGY
More informationL hyperfixation dans le suivi des lymphomes représente-t-elle toujours une maladie active?
L hyperfixation dans le suivi des lymphomes représente-t-elle toujours une maladie active? Thierry Vander Borght UCL Mont-Godinne, Belgique FDG-PET in Lymphoma: Mont-Godinne Experience 03/2000 10/2002:
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationResearch Article The Advantage of PET and CT Integration in Examination of Lung Tumors
Hindawi Publishing Corporation International Journal of Biomedical Imaging Volume 2007, Article ID 17131, 5 pages doi:10.1155/2007/17131 Research Article The Advantage of PET and CT Integration in Examination
More informationPET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationBiases affecting tumor uptake measurements in FDG-PET
Biases affecting tumor uptake measurements in FDG-PET M. Soret, C. Riddell, S. Hapdey, and I. Buvat Abstract-- The influence of tumor diameter, tumor-tobackground activity ratio, attenuation, spatial resolution,
More informationEsophageal Cancer Initially Thought to be Accompanied by a Solitary Metastasis to an Intrathoracic Paraaortic Lymph Node
2012 66 5 417 421 Esophageal Cancer Initially Thought to be Accompanied by a Solitary Metastasis to an Intrathoracic Paraaortic Lymph Node a b* a a a a a a a b ʼ 418 Horio et al. Acta Med. Okayama Vol.
More information